There is one clinical trial.
The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or Jak inhibitors. The strategy will be carried out through a randomised double blind, placebo-controlled clinical trial and will assess comparative rates of infection (prevalence, incidence), severity including mortality, impact on clínical course of the primary diseases and toxicity. Such evaluation will require prospective surveillance to assess the different end-points. Drug interventions in this protocol will follow the Spanish law about off-label use of medicines.
Description: number of new cases divided by number of persons-time at riskMeasure: Incidence rate of new COVID-19 cases in both arms Time: From day 14 after start of treatment up to the end of follow-up: week 27
Description: percentage of cases of COVID 19Measure: Prevalence of COVID-19 cases in both arms Time: 27 weeks after the beginning of the study
Description: Case fatality rate (CFR): the proportion of diagnosed cases of COVID 19 that lead to deathMeasure: Mortality rate secondary to COVID-19 cases in both groups Time: 27 weeks after the beginning of the study
Description: percentage of patients who need admission in an ICU due to COVID 19 infectionMeasure: Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups Time: 27 weeks after the beginning of the study
Description: Presence and type of adverse events at this point.Measure: Adverse events Time: 12 weeks after the start of treatment
Description: Proportion of participants that drop out of studyMeasure: Adverse events Time: 27 weeks after the beginning of the study
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports